Completed Access to Information Requests

About this information

Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).

If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.

*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.

Download datasets of the summaries of completed access to information requests.

Current Search

Report Type

Organization

Disposition

Year

Month

Found 5976 record(s)

Req # A-2023-001393

Adverse Drug Reaction (ADR) for . Report number: E2B_01195522. ADR for Zenhale. Report number: 000335842.

Organization: Health Canada

99 page(s)
July 2024

Req # A-2023-001424

Adverse Drug Reaction (ADR) for Tazemetostat. Report number: E2B_06711165.

Organization: Health Canada

17 page(s)
July 2024

Req # A-2023-001473

Adverse Drug Reactions (ADRs). Report numbers: E2B_ 06770551, E2B_06787144.

Organization: Health Canada

437 page(s)
July 2024

Req # A-2023-001522

Adverse Drug Reaction (ADR). Report number: E2B_05173067.

Organization: Health Canada

54 page(s)
July 2024

Req # A-2023-001534

Adverse Drug Reactions (ADRs). Report numbers: 001067388, E2B_06778630, 001066676, 001067290, 001071749, 001071491, E2B_06785278, E2B_06800937.

Organization: Health Canada

117 page(s)
July 2024

Req # A-2023-001562

Adverse Drug Reactions (ADRs). Report numbers: 001070183, 001070713.

Organization: Health Canada

4 page(s)
July 2024

Req # A-2023-001575

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 23-111864-298.

Organization: Health Canada

8 page(s)
July 2024

Req # A-2023-001615

Adverse Drug Reactions (ADRs). Report numbers: 001069121, E2B_06818695, E2B_06772717.

Organization: Health Canada

13 page(s)
July 2024

Req # A-2023-001622

Adverse Drug Reactions (ADRs) for Mesalimine. Report numbers: E2B_06850804, E2B_06862609. ADRs for CUVITRU. Report numbers: E2B_06897676, E2B_06897774, E2B_06897655, E2B_06897714, E2B_06897705, E2B_06897712, E2B_06897664, E2B_06897688.

Organization: Health Canada

164 page(s)
July 2024

Req # A-2023-001625

Adverse Drug Reactions (ADRs) for Mesalazine. Report numbers: E2B_06860106, E2B_06879090, E2B_06897644. ADRs for Immunoglobulin (human). Report numbers: E2B_06848171, 001069979, 001069986, E2B_06894900, E2B_06839700, E2B_06886486, 001069997.

Organization: Health Canada

129 page(s)
July 2024
Date modified: